Navigation Links
Allarae Healthcare Inc. Announces Signing of Distribution Agreement With Intellect Inc.
Date:12/13/2007

IRVING, Texas, Dec. 13 /PRNewswire-FirstCall/ -- Allarae Healthcare, Inc. (Pink Sheets: ALHI) announced today that it has signed a Distribution Agreement with Intellect, Inc. to sell their entire product line on a non-exclusive basis, worldwide. Intellect, Inc. has developed a broad range of personal health testing kits, several already FDA approved, and personal tracking software for home use. The test kits are ready for market but have not yet been commercialized.

The Company further stated that tests for strep, influenza, cholesterol, and glucose levels are the first to be packaged for immediate sale. Tests for certain other conditions including certain forms of cancer and hepatitis are near completion and will be ready for the market in 2008.

Allarae's President, Phil Matteis, stated that the Company's goal is to become the premier provider of personal health management products. The vision for the company is to provide a complete toolkit that will allow the individual to manage their health more effectively.

This is the second licensing agreement to be signed by the Company. In November of this year a License Agreement was signed with Intellect Holdings, Ltd. for rights to sell its related products and software technology.

"These personal test kits and the related tracking software for individual use are the start of a new era in personal health management and tracking," stated Phil Matteis, President of Allarae. "It will give individuals more control over the management of their own health by giving them the ability to test for numerous disease indicators and track the results on an ongoing basis with their care providers."

The Company stated that additional product announcements will be forthcoming as other products are ready for distribution.

Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of
'/>"/>

SOURCE Allarae Healthcare, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Dr. Paul Bandt Celebrates 35th Anniversary With Desert Radiologists and a History of Healthcare in Las Vegas
5. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
6. MDS to Present at Thomas Weisel Partners Healthcare Conference
7. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
8. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
11. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... BOSTON, Nov. 21 Innerscope Resea... firm specializing in Emotional Response Measureme...utives who will strengthen the,company,s research...,initiatives. , The three appointments, who...de Geoffrey Gill as Chief Financial Officer and Vi...
(Date:11/21/2008)... , COLD SPRING HARBOR, N.Y. (Nov. 21, 2008) Ho...What can the lamprey immune system tell us about e...ations help with efforts to conserve rare species?...duction, and hereditary diseases? Will studies of... , To answer these and other questions in biolog...
(Date:11/21/2008)... WASHINGTON, Nov. 21 New inventio... with a variety of cognitive disabilities lead ful...ience(R) Corporation. Zimman,presented today at t...ington,DC, a meeting organized by The National C...tion to assist people with disabilities. , ...
(Date:11/21/2008)... Winter viruses may be to blame, study suggests ...The season of a baby,s birth may help predict that..., Babies born in autumn -- about four months befo...a 30 percent increased risk of asthma compared to ...study in the first December issue of the American...
Breaking Medicine News(10 mins):Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:A new world of research possibilities with 'Emerging Model Organisms' 2Health News:New Applications for Cognitive Training 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3
...s of vitamin C notwithstanding, British researcher...! It is now said that vitamin C reverses pre eclam...e leading contributors to complications in childbi...n lead onto eclampsia which, when left untreated, ...
...hat causes infectious mononucleosis, Epstein-Barr ...o the development of Hodgkin's disease. But no one...BV and Hodgkin's survival, according to researcher... from Northern California Cancer Center in Union C...
...d on more than 1600 women reveals that parathyroid...ne density and cut the risk of fractures in them. ...ium levels in the body. The new aspect of th...ures has opened up the prospect of the hormone bei...
...n from Mayo Foundation in Rochester, Minnesota has...ble metal stents in the digestive tract of people ...ese patients commonly suffer from obstructions and...ke difficulty in swallowing, if the block is in th...
Other Medicine News:
(Date:11/20/2008)...- The Scandinavian-based drug,development company...on its,lead antimicrobial candidate LTX-109. Pres...wed that the novel lytic peptidomimetic has an ult...er towards killing Staphylococcus,aureus and Stre...gs. In,addition to this it has proven effective a...
(Date:11/19/2008)...significance , , ISELIN, N.J., Nov. 19 /PR...: PARS ) today announced results from its Phase ... drug delivery technology formulated with 3% Diclo... randomized, double-blinded, placebo-controlled st...ny,s 3% Diclofenac Diethanolamine NanoEmulsion cre...
(Date:11/19/2008)...a contract development and,manufacturing organiza...t,phase launch of its contract facility in Delawa...e process, facility and capacity problems commonly...w-volume clinical and,early-stage commercial ster... invest over $100 million and four years to develo...
(Date:11/18/2008)...make a donation or send a Christmas Seals e-card ,...re/ -- Millions will receive Christmas Seals in th...ssociation. These decorative holiday stamps are pa...to 1907 when the Lung Association led efforts to c...alive today have no vivid memories of how widespre...
Breaking Medicine Technology:Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Isogen Launches Major New Facility to Address Global Biopharma Demand 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Julia Zeitlinger named Pew Scholar 3651 1Julia Zeitlinger named Pew Scholar 3651 2INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 1INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 2AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 1AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 2Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide 28R 29 Tablets 21975 1
...ngress of European Hematology,Association (EHA) -,...all/ --,Immunomedics, Inc. , a biopharmaceutical c... to treat cancer and other serious,diseases, today...s,of EHA in Vienna, Austria, showed positive respo... treated with a new,radioimmunotherapy (RAIT) usin...
...ational Reserve" May Also Affect,Alzheimer,s Risk ...e/ -- A new study,suggests that treating risk fact...od pressure and diabetes, may slow the progression...orted today at the,2nd Alzheimer,s Association Int... Washington, DC. , Two new studies presented at th...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: